Special considerations for antihypertensive agents in dialysis patients

Blood Purification

Volumn 29, Issue 2, 2010, Pages 93-98

  Redon, Josep ^a,b   Martinez, Fernando ^a   Cheung, Alfred K ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Antihypertensive drugs; Chronic kidney disease stage 5; Dialysis; Hypertension

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLONIDINE; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; FOSINOPRIL; GUANABENZ; GUANETHIDINE; HYDRALAZINE; LOOP DIURETIC AGENT; LOSARTAN; METHYLDOPA; MINOXIDIL; NADOLOL; RESERPINE; SOTALOL; UNINDEXED DRUG; VASODILATOR AGENT;

BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; VASODILATOR AGENTS;

EID: 77749306446     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245631     Document Type: Review

References (24)

1. Foley RN, Collins AJ: End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648.
2. Ram CV, Fenves AZ: Management of hypertension in hemodialysis patients. Curr Hypertens Rep 2009; 11: 292-298.
3. Kidney Disease Outcome Quality Initiative: Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 2):S1-S246.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
6. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and metaanalysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
7. Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and metaanalysis. Hypertension 2009; 53: 860-866.
8. Schmieder RE: Renin inhibitors: optimal strategy for renal protection. Curr Hypertens Rep 2007; 9: 415-421.
9. Schmid H, Hartmann B, Schiffl H: Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 2009; 14: 185-190.
10. Johnson CA: 2007 Dialysis of Drugs. Verona, Nephrology Pharmacy Associates, 2007.
11. Levin N, Kotanko P, Eckardt KV, Kasiske B, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London G: Blood Pressure in Chronic Kidney Disease Stage 5D - A Position Statement from Kidney Disease: Improving Global Outcomes. New York, Kidney Disease: Improving Global Outcomes, submitted.
12. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ: Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006; 61: 211-220.
13. Kaisar MO, Isbel NM, Johnson DW: Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials 2008; 3: 79-88.
14. Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, Baier M, Schmieder RE: Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol 2008; 69: 425-432.
15. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
16. Herzog CA, Mangrum JM, Passman R: Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-307.
17. Remppis A, Ritz E: Cardiac problems in the dialysis patient: beyond coronary disease. Semin Dial 2008; 21: 319-325.
18. Tong YQ, Hou HM: Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol 2007; 27: 63-69.
19. Vonend O, Rump LC, Ritz E: Sympathetic overactivity - the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330.
20. Zanos S, Mitsopoulos E, Sakellariou G: Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients. Ren Fail 2005; 27: 163-169.
21. Mancia G, Grassi G, Zanchetti A: New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
22. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005; 165: 1410-1419.
23. Staessen JA, Li Y, Thijs L, Wang J-G: Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.
24. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.